ITUS (NYSE:ANIX) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of ITUS (NYSE:ANIX) from a hold rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports.

According to Zacks, “Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. “

Separately, Aegis restated a buy rating on shares of ITUS in a research report on Tuesday, June 2nd.

ITUS stock traded down $0.01 during trading hours on Tuesday, hitting $2.30. The company had a trading volume of 434 shares, compared to its average volume of 247,614. ITUS has a one year low of $1.33 and a one year high of $4.44. The firm has a 50-day moving average of $2.39 and a 200 day moving average of $2.30.

In other news, CEO Amit Kumar purchased 28,000 shares of ITUS stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average price of $2.11 per share, for a total transaction of $59,080.00. Following the transaction, the chief executive officer now owns 262,000 shares of the company’s stock, valued at approximately $552,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lewis H. Titterton, Jr. purchased 40,000 shares of ITUS stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average price of $2.08 per share, for a total transaction of $83,200.00. Following the transaction, the director now directly owns 1,020,326 shares in the company, valued at approximately $2,122,278.08. The disclosure for this purchase can be found here.

ITUS Company Profile

Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.

Further Reading: Growth Stocks

Get a free copy of the Zacks research report on ITUS (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.